论文部分内容阅读
目的:探讨高迁移率族蛋白B1和N1(high mobility group B1 and N1,HMGB1 and HMGN1)在宫颈癌肿瘤细胞中的表达情况与肿瘤浸润淋巴细胞(tumor infiltrating lymphocytes,TILs)的关系。方法:收集2012年4月至2015年9月在天津医科大学附属肿瘤医院就诊的100例早期宫颈癌患者的术后肿瘤组织蜡块标本,其中Ⅰ和Ⅱ期各50例。免疫组织化学方法检测肿瘤组织中HMGB1、HMGN1、CD3和CD8的表达。根据总体的染色强度将HMGB1和HMGN1分别分为高表达组和低表达组;根据有无细胞质表达分别分为有胞质表达组和无胞质表达组。分别比较高、低表达组间及有、无胞质表达组间肿瘤组织内CD3~+和CD8~+细胞数。结果:肿瘤组织内HMGB1和HMGN1的表达强度及有、无胞质表达与患者年龄、FIGO分期、病理分级均没有明显相关性(P>0.05);HMGB1与HMGN1两者的胞质表达呈正相关关系(P<0.05)。HMGB1和HMGN1有胞质表达组的CD3~+和CD8~+细胞较无胞质表达组要高(P<0.05)。结论:宫颈癌细胞HMGB1和HMGN1的胞质表达与肿瘤组织内高水平TILs相关,这一发现有望为宫颈癌的免疫治疗提供新的策略。
Objective: To investigate the relationship between high mobility group B1 and N1 (HMGB1 and HMGN1) expression in cervical cancer cells and tumor infiltrating lymphocytes (TILs). Methods: Tumor specimens were collected from 100 patients with early stage cervical cancer who were treated in Tianjin Cancer Hospital affiliated to Tianjin Medical University from April 2012 to September 2015, of which 50 were in stage Ⅰ and Ⅱ. Immunohistochemistry was used to detect the expression of HMGB1, HMGN1, CD3 and CD8 in tumor tissues. HMGB1 and HMGN1 were divided into high expression group and low expression group according to the overall staining intensity. According to the presence or absence of cytoplasmic expression, HMGB1 and HMGN1 were divided into cytoplasmic expression group and non-cytoplasmic expression group respectively. The numbers of CD3 ~ + and CD8 ~ + cells in the tumor tissue between the high and low expression groups and those with or without cytoplasmic expression were respectively compared. Results: There was no significant correlation between the expression intensity of HMGB1 and HMGN1 and the presence or absence of cytoplasm in tumor tissues, age, FIGO stage and pathological grade (P> 0.05). There was a positive correlation between the expression of HMGB1 and HMGN1 (P <0.05). The levels of CD3 + and CD8 + cells in cytoplasmic HMGB1 and HMGN1 group were higher than those in non-cytoplasmic group (P <0.05). CONCLUSION: The cytoplasmic expression of HMGB1 and HMGN1 in cervical cancer cells is related to the high level of TILs in tumor tissues. This finding is expected to provide a new strategy for the immunotherapy of cervical cancer.